Oppenheimer lowered the firm’s price target on Immunocore (IMCR) to $85 from $88 and keeps an Outperform rating on the shares. The firm notes the company reported year-end 2024 results on Wednesday, with Q4 KIMMTRAK revenues of $84.1M, slightly ahead of expectations. 2025 is a year of execution for Immunocore’s deep clinical stage pipeline, with limited updates anticipated this year, Oppenheimer says. The notable exception is Phase 1 data for Immunocore’s HIV candidate IMCM113V, anticipated in coming weeks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore Holdings: Strong KIMMTRAK Performance and Promising Pipeline Justify Buy Rating
- Immunocore Holdings Faces Trade Secret Challenges Amid Global Competition
- Immunocore Holdings: Strong Kimmtrak Sales and Promising Pipeline Support Buy Rating
- Immunocore Holdings: Sustained Growth and Promising Pipeline Drive Positive Outlook
- Immunocore Holdings Appoints William Pao as Director